Show simple item record

dc.contributor.authorAldámiz-Echevarria, Teresa
dc.contributor.authorBerenguer, Juan
dc.contributor.authorMiralles, Pilar
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorCarrero, Ana
dc.contributor.authorPineda-Tenor, Daniel 
dc.contributor.authorDíez, Cristina
dc.contributor.authorTejerina, Francisco
dc.contributor.authorPérez-Latorre, Leire
dc.contributor.authorBellón, José M
dc.contributor.authorResino, Salvador
dc.identifier.citationPLoS One. 2016; 11(2): e0148537es_ES
dc.description.abstractBACKGROUND: Higher serum levels of adhesion molecules (sICAM-1 and sVCAM-1) are associated with advanced liver fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus. We assessed the relationship between serum levels of adhesion molecules and liver-related events (LRE) or death, in coinfected patients. METHODS: We studied clinical characteristics and outcomes of 182 coinfected patients with a baseline liver biopsy (58 with advanced fibrosis) and simultaneous plasma samples who were followed for median of 9 years. We used receiver-operating characteristic (ROC) curves to calculate optimized cutoff values (OCV) of sICAM-1 and sVCAM-1, defined as the values with the highest combination of sensitivity and specificity for LRE. We used multivariate regression analysis to test the association between OCVs of sICAM-1 and sVCAM-1 and outcomes. The variables for adjustment were age, HIV transmission category, liver fibrosis, baseline CD4+ T-cell counts, antiretroviral therapy, and sustained virologic response (SVR). RESULTS: During the study period 51 patients had SVR, 19 had LRE, and 16 died. The OCVs for LRE were 5.68 Log pg/mL for sICAM-1 and 6.25 Log pg/mL for sVCAM-1, respectively. The adjusted subhazard ratio (aSHR) (95% confidence interval [CI]) of death or LRE, whichever occurred first, for sICAM-1 and sVCAM-1 > OCV were 3.98 ([1.14; 13.89], P = 0.030) and 2.81 ([1.10; 7.19], respectively (P = 0.030). CONCLUSIONS: Serum levels of sICAM-1 and sVCAM-1 can serve as markers of outcome in HIV/HCV-coinfected patients. Therapies targeting necroinflammatory damage and fibrogenesis may have a role in the management chronic hepatitis C.es_ES
dc.description.sponsorshipThis work was supported by grants PI11/01556, PI14/01094, PI11/00245 and CIII/00011 given by Fondo de Investigación de Sanidad en España (FIS) (Spanish Health Funds for Research) and by grants RD12/0017/0004 and RD12/0017/0024 from Plan Nacional R+D+I and cofinanced by ISCIII Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS; Refs INT10/009 and INT12/154). DPTand MAJS are supported by ISCIII grants CM12/ 00043 and CD13/00013, respectively.es_ES
dc.publisherPublic Library of Sciencees_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectCD4-Positive T-Lymphocyteses_ES
dc.subjectFollow-Up Studieses_ES
dc.subjectHIV Infectionses_ES
dc.subjectHepatitis Ces_ES
dc.subjectIntercellular Adhesion Molecule-1es_ES
dc.subjectKaplan-Meier Estimatees_ES
dc.subjectLiver Cirrhosises_ES
dc.subjectRetrospective Studieses_ES
dc.subjectVascular Cell Adhesion Molecule-1es_ES
dc.titleSoluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcomees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderFondo de Investigaciones Sanitariases_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional